Clinical Trials Logo

Terminally Ill clinical trials

View clinical trials related to Terminally Ill.

Filter by:
  • None
  • Page 1

NCT ID: NCT05734781 Recruiting - Terminally Ill Clinical Trials

End-of-life Communication From a Chinese Perspective

Start date: May 4, 2023
Phase:
Study type: Observational

The goal of this observational study is to explore experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers. The main question it aims to answer is: • What are the experiences and perceptions of end-of-life communication in Chinese terminally ill patients, families and healthcare providers? Participants will be invited to either semi-structured in-depth interviews or focus group discussions to share their thoughts.

NCT ID: NCT02036281 Completed - Pain, Intractable Clinical Trials

A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain

Start date: January 2014
Phase: Phase 1
Study type: Interventional

The subjects will be treated with a single dose of SP-SAP. They will receive the study drug SP-SAP via a percutaneous intraspinal catheter, they will be monitored for 4 hours and required to stay in the hospital for 24 hours for precautionary care. Their vital signs will be monitored and recorded immediately following the injection. After the catheter has been removed, the following assessments will be made physical exam including motor and sensory functions, and electrocardiogram. A neurologist will be available for consultation as needed. Beginning dose of SP-SAP will be 1 -mcg for the first cohort. Subsequent single patient dose cohorts as 2, 4, 8, 16, 32, 64 and 90 mcg intrathecally (into the spine). SP-SAP will be accrued and treated after four weeks observation for toxicities between cohorts. Study duration will be up to 6 months from the start of SP-SAP administration.

NCT ID: NCT00982995 Terminated - Nausea Clinical Trials

Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients

HUM21469
Start date: November 2010
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the complete response (no vomiting and no need for other medications to treat nausea) in terminally ill patients suffering from nausea and/or vomiting, who are treated with palonosetron. Another objective is to determine the partial response (relief of nausea and vomiting to the extent that the patient wishes to continue treatment with palonosetron) after being treated with palonosetron. Palonosetron is currently approved by the FDA to prevent nausea and vomiting associated with chemotherapy. The investigators are testing this medication to see if it can help to relieve nausea and vomiting not associated with chemotherapy.

NCT ID: NCT00121004 Completed - Dementia Clinical Trials

A Study to Tailor Advance Directives

Start date: July 2005
Phase: N/A
Study type: Observational

In this study, hospitalized patients will first be surveyed regarding their interest in a traditional advanced directive (AD) and then in a modified AD.